Use of the 21-gene assay is supported by the highest level of evidence (1A) and incorporated in major international guidelines for treatment decisions in patients with N0, ER+, HER2− early breast cancer (EBC) [4,5,6,7]. This evidence concerns the gene ERBB2 and breast carcinoma.